Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 12;11(5):1258–1264. doi: 10.1111/1759-7714.13387

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Changes in serum CXCL16 levels in chemotherapy‐sensitive patients between pre‐ and post‐treatment. (a) Serum CXCL16 levels at pre‐ and post‐chemotherapy, including bevacizumab among patients who achieved stable disease, partial response or complete response after 2–4 courses of treatment (n = 12). CXCL16 levels were significantly decreased. (b) Serum CXCL16 levels among those undergoing therapy without bevacizumab (n = 12). *P < 0.05 (compared with serum CXCL16 level before treatment). Bev, bevacizumab; Chemo, chemotherapy; CXCL16, chemokine (C‐X‐C motif) ligand 16.